Skip to main content
Marker Therapeutics, Inc. logo

Marker Therapeutics, Inc. — Investor Relations & Filings

Ticker · MRKR ISIN · US57055L1070 US Manufacturing
Open in API
Filings indexed 899 across all filing types
Latest filing 2015-07-27 Regulatory Filings
Country US United States of America
Listing US MRKR

About Marker Therapeutics, Inc.

https://markertherapeutics.com/

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing next-generation T cell-based immunotherapies for hematologic malignancies and solid tumors. The company's core technology is its Multi-Antigen Recognizing (MAR) T cell platform, which utilizes natural, non-genetically modified T cells to recognize and kill heterogeneous tumors. This approach is designed to provide durable anti-tumor responses with a favorable safety profile. Its lead product candidate, MT-601, recognizes six tumor-specific antigens and is being evaluated in a Phase 1 study for patients with lymphoma who have relapsed or are ineligible for anti-CD19 CAR-T cell therapy. The technology was originally developed at Baylor College of Medicine.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2015
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated July 21, 2015, by TapImmune Inc. It announces the entry into a material definitive agreement (a License and Assignment Agreement with the Mayo Foundation). The content focuses on the description of the agreement terms, payments, and obligations, but does not contain financial statements or detailed financial performance data. The document is a regulatory announcement of a significant corporate event rather than a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2015-07-27 English
Capital/Financing Update 2015
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated July 17, 2015. It reports the effectiveness of a Post-Effective Amendment to a Registration Statement and details the exercise of Series B warrants resulting in cash proceeds and issuance of common stock. The content focuses on financing activities, specifically the exercise of warrants and issuance of shares, which is a capital raising event. The document length is 2615 characters, which is relatively short and typical for an 8-K filing. The key content is about financing and capital structure changes, not a full financial report or earnings release. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2015-07-23 English
Capital/Financing Update 2015
Capital/Financing Update Classification · 95% confidence The document is a Form S-1 Registration Statement filed with the SEC, dated July 20, 2015, for TapImmune Inc. It is a registration statement under the Securities Act of 1933, used for registering securities for public offering. The text includes detailed information about the securities being registered, the business overview, product candidates, risk factors, management discussion, and other disclosures typical of an S-1 filing. This type of document is a capital markets filing related to fundraising and securities registration, not an annual report, earnings release, or other financial report. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is the actual registration statement, not just an announcement of a report. Hence, the classification is CAP with high confidence.
2015-07-20 English
Capital/Financing Update 2015
Capital/Financing Update Classification · 95% confidence The document is a prospectus filed pursuant to Rule 424(b)(3) under the Securities Act, which is a registration statement for the resale of common stock and warrants. It details the securities being offered, the business overview, product candidates, risk factors, management discussion, and other related information typical of a prospectus. This type of document is related to capital raising and financing activities, specifically the offering and resale of shares and warrants. Therefore, it fits the category of Capital/Financing Update (CAP). The document is lengthy (15,000 characters) and contains detailed information about the offering, not just an announcement or a brief summary, so it is not a Report Publication Announcement or Regulatory Filing. Hence, the classification is CAP with high confidence.
2015-07-17 English
Regulatory Filings 2015
Regulatory Filings
2015-07-17 English
Regulatory Filings 2015
Regulatory Filings Classification · 95% confidence The document is a letter from TapImmune Inc. to the U.S. Securities and Exchange Commission requesting acceleration of the effectiveness of a Post-Effective Amendment No. 2 to a Registration Statement on Form S-3/A on Form S-1. It references filings related to securities registration and does not contain financial statements or detailed financial data. The document is short (2223 characters) and serves as a formal request related to regulatory filing procedures rather than a financial report or announcement of results. It is not an Annual Report, Earnings Release, or any detailed financial or management report. It is also not a certification or insider transaction report. The content fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2015-07-15 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.